---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-22-000103"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2022-08-12T23:59:59+00:00"
generated_at: "2026-06-24T00:27:42.373042+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Humacyte Q2 net income $36.9M driven by non-cash gains; HAVs show promise in Ukraine

## Summary
- Cash $189.0M as of June 30, 2022; company expects runway through 2024, past potential HAV approval in vascular trauma.
- Net income $36.9M vs net loss $17.2M in Q2 2021; driven by $55.4M non-cash gain from contingent earnout remeasurement.
- Revenue $1.3M (grants), up from $0.7M; R&D expense $14.7M, G&A $5.2M.
- HAVs implanted in Ukraine under humanitarian initiative reportedly functioning and infection-free, saving limbs.
- Appointed Diane Seimetz to Board and Shamik Parikh as CMO; preclinical small-diameter HAV data in CABG presented.

## SEC filing metadata
- accession: 0001818382-22-000103
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2022-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838222000103/0001818382-22-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838222000103/huma-20220812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-22-000103
- JSON: https://secwatch.observer/filing/0001818382-22-000103.json
- Plain text: https://secwatch.observer/filing/0001818382-22-000103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.